Alumis reported that its TYK2 inhibitor envudeucitinib failed to meet efficacy goals in a Phase 2b systemic lupus erythematosus (Lumus) study, showing no overall response-rate improvement in the total population. The company pointed to a prespecified subgroup analysis in patients with an interferon gene signature (IFNGS-high), and said it plans to pursue Phase 3 development in that subset.